Project Grant R21CA299543
Award Date
6/1/25
Completion Date
5/31/27
Dollars Obligated
$409K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This federal Project Grant award in the amount of $1,271,780.00 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The funding supports research by the University of Pittsburgh to develop small molecule adaptors for precisely controlling and reprogramming universal chimeric antigen receptor (CAR) T cell therapies. Specifically, the research aims to: 1) Create small molecule adaptors that can target multiple antigens on tumor cells and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $176,712 to the University of Pittsburgh to conduct research on how tumor-derived heat shock proteins prime T cell responses to eliminate emerging, nascent tumors. The project aims to develop a new mouse model to test the importance of CD91-mediated signaling in response to tumor-derived heat shock proteins for cancer immunosurveillance. Specifically, the research will...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $636,222 to the University of Pittsburgh to define the mechanisms by which certain bacteria associated with improved response to immune checkpoint inhibitor (ICI) cancer therapies modulate tumor immunity. The project aims to determine whether ICI-associated bacteria can metabolize tryptophan into aryl hydrocarbon receptor (AhR) ligands that enhance anti-tumor CD8+ T cell...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
The National Cancer Institute (NCI) has awarded a $435,773 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Maryland, Baltimore (UMB) to develop an engineered prodrug capable of selectively delivering potent cytotoxins to malignant tumor cells. The goal is to leverage hyperactive membrane-anchored serine proteases (MASPs) on the surface of tumor cells to activate the prodrug and selectively kill cancer cells, particularly in ovarian, lung, and colon cancers. The...
This $1,130,538 federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to target the tumor-specific Tn antigen in pancreatic ductal adenocarcinoma (PDAC). The University of Louisville, as the prime awardee, will: Determine how the Tn antigen enhances PDAC tumor progression and identify Tn-expressing glycoproteins using mouse models and clinical specimens. Validate the role of natural killer cells in the...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.396 - Cancer Biology Research) totaling $585,931 to the University of Pittsburgh to conduct research on evaluating and selecting representative cancer models for precision medicine. The key objectives are to: (1) identify and clinically annotate prevalent subclones and tumor microenvironment cell types in breast cancer; (2) perform subclone-based congruence and selection for cancer models; and (3) decipher temporal changes in...
This $546,625 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) is focused on developing a novel immunochemotherapy approach for treating metastatic colorectal cancer (mCRC). The key products and services to be delivered under this 5-year award (1/9/2025 - 12/31/2029) include: Developing and characterizing a nanocarrier platform (PCL-CP) capable of co-delivering siRNA targeting the IRHOM1 gene and a prodrug conjugate of camptothecin...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) is funding research to develop a novel cancer therapy with both immuno-activating and oncology-targeting capabilities to treat triple negative breast cancer. The $661,072 award to Northwestern University, with a subcontract to Exomira Medicine Inc., aims to advance an IND-enabling study for a first-in-class small molecule inhibitor targeting the USP22 oncogene. This multifaceted approach...
This $429,123 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of improved inhibitors that selectively target the CBX8 chromatin reader domain. The research team at Purdue University is using DNA-encoded library screening approaches to identify CBX8-selective inhibitors with enhanced cellular activity compared to current probes. The goal is to validate the selective inhibition of CBX8 as a viable, non-toxic therapeutic...